R-vac (rubella vaccine) / Serum Institute of India - LARVOL DELTA

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=1200 | Recruiting | Sponsor: PATH | Trial completion date: Nov 2027 ➔ Mar 2028 | Trial primary completion date: Nov 2027 ➔ Mar 2028

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=1200 | Recruiting | Sponsor: PATH | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Malaria

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=1200 | Not yet recruiting | Sponsor: PATH

New P2 trial • Infectious Disease • Malaria

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial. (PubMed, Lancet) - P3 | "When compared with a licensed, quadrivalent meningococcal conjugate vaccine, and given alongside other routine vaccines, a single dose of NmCV-5 was safe and elicited a non-inferior immune response in infants aged 9 months and young children aged 15 months."

Head-to-Head • Journal • P3 data • CNS Disorders • Infectious Disease • Measles • Meningococcal Infections • Rubella

A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial. (PubMed, Lancet) - "The safety and immunogenicity data support the accelerated development of the MRV-MNP."

Journal • P1/2 data • Infectious Disease • Measles • Rubella